Baxter International Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated October 31, 2018, reports the issuance of an earnings press release for the quarterly period ended September 30, 2018. The filing serves to disseminate financial results and non-GAAP measures to investors.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing these figures but does not include the data within the body of this report.
The document defines the following non-GAAP financial measures used in the referenced press release:
- Adjusted Income Metrics: Adjusted income from continuing operations, adjusted diluted earnings per share, adjusted operating income, and adjusted pre-tax income.
- Adjusted Expense Metrics: Adjusted gross margin, marketing and administrative expenses, research and development expenses, Claris settlement, other (income) expense, and income tax expense.
- Sales Measures: Constant currency sales (excluding foreign exchange rate changes) and operational sales (excluding foreign exchange, U.S. cyclophosphamide generic competition, and specific acquisitions).
- Cash Flow: Free cash flow, defined as operating cash flow less capital expenditures.
Material Changes and Special Items
The filing notes that special items are excluded from non-GAAP measures because they are highly variable, difficult to predict, or unusual. Specific exclusions mentioned include:
- Intangible asset amortization.
- Impact of generic competition for U.S. cyclophosphamide.
- Acquisitions of the Claris Injectables business and the RECOTHROM and PREVELEAK products.
The text does not quantify the material changes versus the prior comparable period.
Guidance, Outlook, and Risks
Management utilizes these non-GAAP measures for internal financial planning, monitoring business unit performance, and determining incentive compensation. The filing cautions that future events or new information may result in different actual results than the estimates provided in the press release. It also warns that non-GAAP measures may differ from similar measures used by other companies.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release Dated October 31, 2018) for specific revenue, earnings, and cash flow figures.
- Examine the reconciliation tables in the press release to understand the difference between GAAP and non-GAAP results.
- Verify the specific financial impact of the Claris Injectables acquisition and RECOTHROM/PREVELEAK products on operational sales.
- Assess the magnitude of intangible asset amortization excluded from adjusted operating income.
- Confirm the impact of foreign currency exchange rates on reported net sales.